Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Notes Payables: 2015-2017

Historic Notes Payables for Gyre Therapeutics (GYRE) over the last 2 years, with Dec 2017 value amounting to $5.1 million.

  • Gyre Therapeutics' Notes Payables fell 73.79% to $5.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was $5.1 million, marking a year-over-year decrease of 73.79%. This contributed to the annual value of $5.1 million for FY2017, which is 73.79% down from last year.
  • According to the latest figures from Q4 2017, Gyre Therapeutics' Notes Payables is $5.1 million, which was down 7.34% from $5.5 million recorded in Q3 2017.
  • In the past 5 years, Gyre Therapeutics' Notes Payables registered a high of $34.8 million during Q3 2015, and its lowest value of $5.1 million during Q4 2017.
  • Its 3-year average for Notes Payables is $20.8 million, with a median of $24.5 million in 2016.
  • Data for Gyre Therapeutics' Notes Payables shows a maximum YoY plummeted of 81.50% (in 2017) over the last 5 years.
  • Over the past 3 years, Gyre Therapeutics' Notes Payables (Quarterly) stood at $33.7 million in 2015, then crashed by 42.50% to $19.4 million in 2016, then slumped by 73.79% to $5.1 million in 2017.
  • Its Notes Payables stands at $5.1 million for Q4 2017, versus $5.5 million for Q3 2017 and $5.8 million for Q2 2017.